Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.

Anti-cancer drugs - 1 Aug 2015

Wang Emilie, Karedan Tezo, Perez Cesar A

Abstract excerpt

During the past two decades, several key somatic mutations associated with development and progression of differentiated thyroid cancer (DTC) have been revealed. Historically, the treatment for advanced DTC is challenging after patients become refractory to radioactive iodine. The response to doxorubicin, the only chemotherapy agent approved by the US Food and Drug Administration, is disappointing either as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Piperidines

Share to Quinolines

Share to Sorafenib

Share to Treatment Failure

Source

Identifiers

PMID: 25974026
DOI: 10.1097/CAD.0000000000000247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.PMID 25974026Read ↗

Novel targeted therapies and immunotherapy for advanced thyroid cancers.Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Semantic proximity Read ↗

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read ↗

Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer.Semantic proximity Read ↗

New Therapies for Advanced Thyroid Cancer.Semantic proximity Read ↗

Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.Semantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

Update on the molecular diagnosis and targeted therapy of thyroid cancer.Semantic proximity Read ↗

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.